{"id":324010,"date":"2026-03-04T09:27:27","date_gmt":"2026-03-04T01:27:27","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=324010"},"modified":"2026-03-04T09:27:54","modified_gmt":"2026-03-04T01:27:54","slug":"cirrus-therapeutics-announces-strategic-expansion-to-singapore-and-other-key-updates-supporting-its-growth-as-a-leading-global-ocular-immunology-company","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=324010","title":{"rendered":"Cirrus Therapeutics Announces Strategic Expansion To Singapore And Other Key Updates Supporting Its Growth As A Leading Global Ocular Immunology Company"},"content":{"rendered":"\n<p><strong>CAMBRIDGE, Mass. and SINGAPORE, March 4 (Bernama-GLOBE NEWSWIRE) &#8212;<\/strong>&nbsp;Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology company advancing first-in-class and best-in-class therapies to extend the ocular healthspan of patients with chronic blinding diseases.<\/p>\n\n\n\n<ul><li><strong>Expands to Singapore and appoints Singapore site head.\u00a0<\/strong>Complementing its UK science origins and US infrastructure, Cirrus has now established an R&amp;D site in Singapore, further expanding its global footprint and gaining access to Asia-Pacific, one of the world\u2019s fastest-growing biopharma markets. Si Hui Tan, PhD has been appointed as Director, Pipeline and Site Head, Singapore. Dr. Tan most recently led the first-in-class liver regeneration program at Lerna Biopharma, a multi-site biotech where she was also a founding member. Dr. Tan holds a PhD in Cancer Biology from Stanford University.<\/li><\/ul>\n\n\n\n<p><a href=\"https:\/\/mrem.bernama.com\/viewsm.php?idm=53661\">https:\/\/mrem.bernama.com\/viewsm.php?idm=53661<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and SINGAPORE, March 4 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology company advancing first-in-class and best-in-class therapies to extend the ocular healthspan of patients with chronic blinding diseases. Expands to Singapore and appoints Singapore site head.\u00a0Complementing its UK science [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/324010"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=324010"}],"version-history":[{"count":1,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/324010\/revisions"}],"predecessor-version":[{"id":324016,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/324010\/revisions\/324016"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=324010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=324010"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=324010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}